Usefulness of Dual-Point Amyloid PET Scans in Appropriate Use Criteria: A Multicenter Study

2018 ◽  
Vol 65 (3) ◽  
pp. 765-779 ◽  
Author(s):  
Fermín Segovia ◽  
Manuel Gómez-Río ◽  
Raquel Sánchez-Vañó ◽  
Juan Manuel Górriz ◽  
Javier Ramírez ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Amyloid Pet ◽  
Appropriate Use Criteria ◽  
Appropriate Use ◽  
Pet Scans

scholarly journals Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria

Medicine ◽  
2019 ◽  
Vol 98 (29) ◽  
pp. e16509
Author(s):  
Eva María Triviño-Ibáñez ◽  
Raquel Sánchez-Vañó ◽  
Pablo Sopena-Novales ◽  
Juan Carlos Romero-Fábrega ◽  
Antonio Rodríguez-Fernández ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Clinical Management ◽  
Amyloid Pet ◽  
Appropriate Use Criteria ◽  
Appropriate Use

Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid-PET

2018 ◽  
Vol 14 (8) ◽  
pp. 1088-1098 ◽  
Author(s):  
Daniele Altomare ◽  
Clarissa Ferrari ◽  
Cristina Festari ◽  
Ugo Paolo Guerra ◽  
Cristina Muscio ◽  
...  
Keyword(s):  
Amyloid Imaging ◽  
Amyloid Pet ◽  
Appropriate Use Criteria ◽  
Appropriate Use ◽  
Quantitative Appraisal

scholarly journals Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project

2019 ◽  
Vol 15 (11) ◽  
pp. 1458-1467 ◽  
Author(s):  
Arno de Wilde ◽  
Rik Ossenkoppele ◽  
Wiesje Pelkmans ◽  
Femke Bouwman ◽  
Colin Groot ◽  
...  
Keyword(s):  
Amyloid Pet ◽  
Appropriate Use Criteria ◽  
Memory Clinic ◽  
Appropriate Use

scholarly journals Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria

2016 ◽  
Vol 41 (1-2) ◽  
pp. 80-92 ◽  
Author(s):  
Michael Grundman ◽  
Keith A. Johnson ◽  
Ming Lu ◽  
Andrew Siderowf ◽  
Grazia Dell''Agnello ◽  
...  
Keyword(s):  
Cognitive Decline ◽  
Management Plan ◽  
Amyloid Imaging ◽  
Amyloid Pet ◽  
Appropriate Use Criteria ◽  
Appropriate Use ◽  
Diagnosis And Management ◽  
Positron Emission ◽  
Before And After ◽  
The Impact

Background: Published appropriate use criteria (AUC) describe patients for whom amyloid positron emission tomography (PET) might be most useful. This study compared the impact of amyloid PET on diagnosis and management in subjects likely to either meet or not meet AUC. Methods: Physicians provided a provisional diagnosis and management plan for patients presenting with cognitive decline before and after amyloid PET imaging with florbetapir F 18. Participants were classified as AUC-like or not, based on the prescan diagnosis and demographic features. Results: In all, 125 of 229 participants (55%) were classified as AUC-like. Sixty-two percent of the AUC-like subjects had a change in diagnosis after scanning compared with 45% of the non-AUC subjects (p = 0.011). Both groups demonstrated high rates of change in their management plans after scanning (88.0% for AUC-like cases, 85.6% for non-AUC cases). Conclusions: The impact of amyloid imaging on diagnosis and planned management was maintained and, if anything, amplified in AUC-like patients.

scholarly journals Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education

2013 ◽  
Vol 9 (4) ◽  
pp. e106-e109 ◽  
Author(s):  
Keith A. Johnson ◽  
Satoshi Minoshima ◽  
Nicolaas I. Bohnen ◽  
Kevin J. Donohoe ◽  
Norman L. Foster ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Pet Imaging ◽  
Amyloid Pet ◽  
Appropriate Use Criteria ◽  
Appropriate Use ◽  
Amyloid Pet Imaging

scholarly journals Update on Appropriate Use Criteria for Amyloid PET Imaging: Dementia Experts, Mild Cognitive Impairment, and Education

2013 ◽  
Vol 54 (7) ◽  
pp. 1011-1013 ◽  
Author(s):  
K. A. Johnson ◽  
S. Minoshima ◽  
N. I. Bohnen ◽  
K. J. Donohoe ◽  
N. L. Foster ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Pet Imaging ◽  
Amyloid Pet ◽  
Appropriate Use Criteria ◽  
Appropriate Use ◽  
Amyloid Pet Imaging

#3041 High prevalence of lifetime depressive symptoms in patients referred for clinical amyloid-PET: a retrospective study

2021 ◽  
Vol 92 (8) ◽  
pp. A9.1-A9
Author(s):  
Anna Fitzgerald ◽  
Flavia Loreto ◽  
Mara Golemme ◽  
Zarni Win ◽  
Neva Patel ◽  
...  
Keyword(s):  
Older Adults ◽  
Cognitive Impairment ◽  
Depressive Symptoms ◽  
Amyloid Pet ◽  
Onset Age ◽  
Appropriate Use Criteria ◽  
Memory Clinic ◽  
Appropriate Use ◽  
History Of ◽  
History Of Depression

Objectives/AimsDepression has been reported as a possible risk factor for Alzheimer’s Disease, but also as one of the clinical features of Alzheimer’s as well as other dementias. Further, depression has long been associated with cognitive impairment in the absence of neurodegeneration (Connors et al. 2018). Here we sought to ascertain the prevalence of clinical depression in patients meeting widely accepted Appropriate Use Criteria for Amyloid PET Imaging (API). We examined the prevalence of lifetime depression in patients undergoing clinical API in a real-world clinical setting and compared our findings with population data from community-dwelling older adults. We also examined whether rates of depression were higher in amyloid positive or negative groups.MethodsOne-hundred-and-eighty-five older adults (mean age 67.079.37, 49% females) underwent diagnostic workup, including API, at the Imperial Memory Clinic between January 2017 and June 2019. API was performed in line with appropriate use criteria after multidisciplinary team discussion. History of depressive symptoms and features of depression were evaluated through a review of hospital records and clinical correspondence. Patients were defined as having a history of depression if there was evidence of previous or current depressive symptoms and/or of a formal diagnosis of depression in their clinical records.ResultsBased on visual reads, 83 individuals had positive Amyloid-PET scans and 102 were negative. Overall, 102 (55%) patients(mean age=66.758.99, 56% females) had a history of lifetime depressive symptoms, compared with just 12 and 19% of elderly individuals in the general population (McDougall et al. 2007; Biddulph et al. 2014). Of the 92 patients for whom further information regarding depression onset were available, 54 (58.7%) had early symptom onset (age <60), and 38 (41.3%) had late symptom onset (age ≥s60). At the time of the clinical assessment at the Imperial Memory Clinic, 71 of those 102 (69.6%) were on active treatment for depression. Finally, depression was not associated with amyloid status (χ2(1) =1.12p=.26), with 42 (41.2%) amyloid-positive and 60 (58.8%) amyloid-negative patients reporting a history of depression.ConclusionsOver half of patients with suspected cognitive impairment and meeting appropriate use criteria for clinical API had a history of depression, regardless of amyloid status. Depression is an important but incompletely understood factor in referral for evaluation with Amyloid-PET.

Appropriate use criteria for dementia amyloid imaging in Switzerland – mini-review and statement on behalf of the Swiss Society of Nuclear Medicine and the Swiss Memory Clinics

2020 ◽  
Author(s):  
Freimut Dankwart Juengling ◽  
Gilles Allenbach ◽  
Matthias Bruehlmeier ◽  
Bernd Klaeser ◽  
Michael Peter Wissmeyer ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Beta Amyloid ◽  
Amyloid Pet ◽  
Swiss Society ◽  
Appropriate Use Criteria ◽  
Appropriate Use ◽  
Diagnosis Of Dementia ◽  
Memory Clinics ◽  
Compulsory Health Insurance ◽  
The Brain

AbstractWhile FDG-PET imaging of the brain for the differential diagnosis of dementia has been covered by the compulsory health insurance in Switzerland for more than a decade, beta-amyloid-PET just recently has been added to the catalogue of procedures that have been cleared for routine use, provided that a set of appropriate use criteria (AUC) be followed. To provide guidance to dementia care practitioners, the Swiss Society of Nuclear Medicine and the Swiss Memory Clinics jointly report a mini-review on beta-amyloid-PET and discuss the AUC set into effect by the Swiss Federal Office of Public Health, as well as their application and limitations.

scholarly journals Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

2013 ◽  
Vol 9 (1) ◽  
pp. E1-E16 ◽  
Author(s):  
Keith A. Johnson ◽  
Satoshi Minoshima ◽  
Nicolaas I. Bohnen ◽  
Kevin J. Donohoe ◽  
Norman L. Foster ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Molecular Imaging ◽  
Task Force ◽  
Amyloid Imaging ◽  
Amyloid Pet ◽  
Appropriate Use Criteria ◽  
Appropriate Use
Sign in / Sign up

Export Citation Format

Share Document